The Company sold 444,038 shares of Hisamitsu Pharmaceutical Co., Inc. held, at 6,082 yen per share, totaling 2,700 million yen, and will record special gains of 2,543 million yen in the fiscal year ending March 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4914","jir_company_name":"Takasago International Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4914-20260224-01.pdf","jir_short_summary":"The Company sold 444,038 shares of Hisamitsu Pharmaceutical Co., Inc. held, at 6,082 yen per share, totaling 2,700 million yen, and will record special gains of 2,543 million yen in the fiscal year ending March 2026.","jir_summary":"### Overview of Tender Offer Application Results\nThe Company applied to the tender offer conducted by Taiyo Kosan Co., Ltd. for 444,038 ordinary shares of Hisamitsu Pharmaceutical Co., Inc. held (including shares held by the trading partner shareholders' association), and all shares were purchased. The sale price was 6,082 yen per share, with a total sale amount of 2,700 million yen. Settlement will commence from February 27, 2026.\n\n### Impact on Earnings and Future Outlook\nFollowing the successful tender offer, the Company will record special gains of 2,543 million yen from the sale of investment securities in both the standalone and consolidated financial results for the fiscal year ending March 2026. Please note that the full-year consolidated earnings forecast for the fiscal year ending March 2026 was already disclosed in the \u201cNotice of Revision to Earnings Forecast\u201d dated February 13, 2026.","jir_financial_highlights":"Number of Shares Sold: 444,038 shares (Unknown)\nSale Price (per share): 6,082 yen (Unknown)\nTotal Sale Amount: 2,700 million yen (Unknown)\nRecorded Special Gains: 2,543 million yen (Unknown)\nSettlement Start Date: 2026-02-27 (Unknown)","jir_category":"","jir_hashtags":"#TakasagoInternationalCorporation, #TenderOffer, #TOB, #SpecialGains, #JapaneseStocks","jir_key_figures":"Number of Shares Sold: 444,038 shares (including shares held by Hisamitsu Pharmaceutical trading partner shareholders' association)\nSale Price (per share): 6,082 yen\nTotal Sale Amount: 2,700 million yen","jir_meta_title":"Takasago International Sells 444,038 Shares of Hisamitsu Pharmaceutical for 2,700 Million Yen, Recording Special Gains of 2,543 Million Yen","jir_meta_description":"Takasago International Corporation sold 444,038 shares of Hisamitsu Pharmaceutical Co., Inc. at 6,082 yen per share and will record special gains of 2,543 million yen in the fiscal year ending March 2026. Settlement to begin on February 27, 2026.","jir_og_title":"Takasago International Announces Recording of Special Gains from Sale of Hisamitsu Pharmaceutical Shares","jir_og_description":"Takasago International sold 444,038 shares of Hisamitsu Pharmaceutical and recorded special gains of 2,543 million yen. Settlement will start on February 27, 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9256,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-30745","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n